---
title: "Alirocumab - Atherosclerosis"
sidebar: mydoc_sidebar
permalink: db09302-mesh-d050197-1.html
toc: false 
---


Path ID: `DB09302_MESH_D050197_1`
{% include image.html url="images/db09302-mesh-d050197-1.png" file="db09302-mesh-d050197-1.png" alt="db09302-mesh-d050197-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C571059 | alirocumab | Drug |
| UniProt:Q8NBP7 | Proprotein convertase subtilisin/kexin type 9 | Protein |
| GO:0090118 | receptor-mediated endocytosis involved in cholesterol transport | BiologicalProcess |
| HP:0003141 | Increased LDL cholesterol concentration | PhenotypicFeature |
| HP:0031678 | Atherosclerotic lesion | PhenotypicFeature |
| MESH:D050197 | Atherosclerosis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Alirocumab | DECREASES ACTIVITY OF | Proprotein Convertase Subtilisin/Kexin Type 9 |
| Proprotein Convertase Subtilisin/Kexin Type 9 | NEGATIVELY REGULATES | Receptor-Mediated Endocytosis Involved In Cholesterol Transport |
| Receptor-Mediated Endocytosis Involved In Cholesterol Transport | NEGATIVELY CORRELATED WITH | Increased Ldl Cholesterol Concentration |
| Increased Ldl Cholesterol Concentration | POSITIVELY CORRELATED WITH | Atherosclerotic Lesion |
| Atherosclerotic Lesion | MANIFESTATION OF | Atherosclerosis |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB09302](https://go.drugbank.com/drugs/DB09302)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109540/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109540/)
  - [https://en.wikipedia.org/wiki/Alirocumab#Pharmacology](https://en.wikipedia.org/wiki/Alirocumab#Pharmacology)
